Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286845 · ClinicalTrials.gov registry record
Use of the MiCK Assay for Apoptosis in AML
A clinical trial, sponsored by Pierian Biosciences.
- Completed
- Registry status
- 50
- Enrollment target
NCT00286845 is a clinical trial that has completed, run by Pierian Biosciences. The registered enrollment target is 50 participants.
The verdict
NCT00286845 has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
A previous preliminary study performed at Vanderbilt University with funding from the Leukemia Society of America demonstrated that the response of leukemia cells in vitro to the chemotherapeutic agent idarubicin in the microculture kinetic assay for apoptosis (MiCK assay) predicted survival in patients with newly diagnosed acute myeloid leukemia (AML). In this previous study, achievement of complete response (CR) to induction therapy with idarubicin and cytarabine was used as the clinical indicator for determining whether leukemia specimens taken prior to treatment were sensitive or not sensitive in the MiCK assay. This group of patients has been followed for 7 years and their long term survival rates show that their responses in the MiCK assay to idarubicin but not cytarabine predict survival. In the present proposal a separate group of patients with newly diagnosed AML will be recruited to provide leukemia cell samples that will be used to establish criteria for sensitivity and non-sensitivity to idarubicin and cytarabine in the MiCK assay. The achievement of CR will be used to determine in vitro sensitivity as it was done in the previous study. With the in vitro sensitivities as determined in this proposed study, the long term survivals of patients in the previous study will be analyzed prospectively. The proposed study is expected to have an approximate duration of one year. Patient population will include newly diagnosed AML patients with both de novo AML and AML arising from a previously diagnosed myelodysplastic syndrome. The study will not include patients with previously treated leukemia that has relapsed
Interventions
- DRUG Standard Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286845
The ClinicalTrials.gov registry entry for NCT00286845 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pierian Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard Chemotherapy is the first listed.
NCT00286845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00286845 about?
NCT00286845 is a clinical study titled "Use of the MiCK Assay for Apoptosis in AML". A previous preliminary study performed at Vanderbilt University with funding from the Leukemia Society of America demonstrated that the response of leukemia cells in vitro to the chemotherapeutic agent idarubicin in the microculture kinetic assay for apoptosis (MiCK assay) predicted survival in pati...
What is the current status of trial NCT00286845?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2006-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00286845?
The interventions under investigation include: Standard Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00286845?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.